Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases.

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Patel, DD; Antoni, C; Freedman, SJ; Levesque, MC; Sundy, JS

Published Date

  • September 2017

Published In

Volume / Issue

  • 140 / 3

Start / End Page

  • 685 - 687

PubMed ID

  • 28506849

Pubmed Central ID

  • 28506849

Electronic International Standard Serial Number (EISSN)

  • 1097-6825

Digital Object Identifier (DOI)

  • 10.1016/j.jaci.2017.04.029

Language

  • eng

Conference Location

  • United States